161 related articles for article (PubMed ID: 12498805)
1. Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy.
Helguera G; Morrison SL; Penichet ML
Clin Immunol; 2002 Dec; 105(3):233-46. PubMed ID: 12498805
[No Abstract] [Full Text] [Related]
2. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
Xiang J
Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
[TBL] [Abstract][Full Text] [Related]
3. Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.
Müller D
BioDrugs; 2014 Apr; 28(2):123-31. PubMed ID: 24018469
[TBL] [Abstract][Full Text] [Related]
4. Antibody-cytokine fusion proteins.
Kontermann RE
Arch Biochem Biophys; 2012 Oct; 526(2):194-205. PubMed ID: 22445675
[TBL] [Abstract][Full Text] [Related]
5. Antibody-cytokine fusion proteins: applications in cancer therapy.
Ortiz-Sánchez E; Helguera G; Daniels TR; Penichet ML
Expert Opin Biol Ther; 2008 May; 8(5):609-32. PubMed ID: 18407765
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies.
Helguera G; Rodríguez JA; Daniels TR; Penichet ML
Cancer Immunol Immunother; 2007 Sep; 56(9):1507-12. PubMed ID: 17310381
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy of cancer.
Rosenberg SA
Important Adv Oncol; 1992; ():17-38. PubMed ID: 1582673
[No Abstract] [Full Text] [Related]
8. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.
Mizokami MM; Hu P; Khawli LA; Li J; Epstein AL
Hybrid Hybridomics; 2003 Aug; 22(4):197-207. PubMed ID: 14511565
[TBL] [Abstract][Full Text] [Related]
9. Antibody-cytokine fusion proteins for the therapy of cancer.
Helguera G; Penichet ML
Methods Mol Med; 2005; 109():347-74. PubMed ID: 15585931
[TBL] [Abstract][Full Text] [Related]
10. Antibody-cytokine fusion proteins: innovative weapons in the war against cancer.
Dela Cruz JS; Huang TH; Penichet ML; Morrison SL
Clin Exp Med; 2004 Oct; 4(2):57-64. PubMed ID: 15672942
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic antibodies and antibody fusion proteins.
Rohrbach P; Broders O; Toleikis L; Dübel S
Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
[No Abstract] [Full Text] [Related]
12. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
Young PA; Morrison SL; Timmerman JM
Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
[TBL] [Abstract][Full Text] [Related]
13. Recombinant antibody fusion proteins for cancer immunotherapy.
Reisfeld RA; Gillies SD
Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
[No Abstract] [Full Text] [Related]
14. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy.
Valedkarimi Z; Nasiri H; Aghebati-Maleki L; Majidi J
Biomed Pharmacother; 2017 Nov; 95():731-742. PubMed ID: 28888210
[TBL] [Abstract][Full Text] [Related]
15. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
Murer P; Neri D
N Biotechnol; 2019 Sep; 52():42-53. PubMed ID: 30991144
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy of malignant diseases].
Dorval T; Michon J; Tartour E; Fridman WH
Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
[TBL] [Abstract][Full Text] [Related]
17. Molecular approaches to cancer immunotherapy.
Forni G; Cavallo F; Consalvo M; Allione A; Dellabona P; Casorati G; Giovarelli M
Cytokines Mol Ther; 1995 Dec; 1(4):225-48. PubMed ID: 9384678
[TBL] [Abstract][Full Text] [Related]
18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
19. Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo.
Fukumoto H; Nishio K; Ohta S; Hanai N; Fukuoka K; Ohe Y; Sugihara K; Kodama T; Saijo N
Int J Cancer; 1999 Aug; 82(5):759-64. PubMed ID: 10417777
[TBL] [Abstract][Full Text] [Related]
20. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
Wels W; Groner B; Hynes NE
Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():113-28. PubMed ID: 8815001
[No Abstract] [Full Text] [Related]
[Next] [New Search]
